BR0212327A - Derivados de 2-(d-fenóxi)piridina substituìda heterocìclica e compostos correlatos como bloqueadores de canal de sódio para o tratamento de dano neuronal e condições neurodegenerativas - Google Patents

Derivados de 2-(d-fenóxi)piridina substituìda heterocìclica e compostos correlatos como bloqueadores de canal de sódio para o tratamento de dano neuronal e condições neurodegenerativas

Info

Publication number
BR0212327A
BR0212327A BR0212327-4A BR0212327A BR0212327A BR 0212327 A BR0212327 A BR 0212327A BR 0212327 A BR0212327 A BR 0212327A BR 0212327 A BR0212327 A BR 0212327A
Authority
BR
Brazil
Prior art keywords
treatment
neuronal damage
neurodegenerative conditions
phenoxy
sodium channel
Prior art date
Application number
BR0212327-4A
Other languages
English (en)
Inventor
Bin Shao
R Richard Goehring
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BR0212327A publication Critical patent/BR0212327A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"DERIVADOS DE 2-(4-FENóXI)PIRIDINA SUBSTITUìDA HETEROCìCLICA E COMPOSTOS CORRELATOS COMO BLOQUEADORES DE CANAL DE SóDIO PARA O TRATAMENTO DE DANO NEURONAL E CONDIçõES NEURODEGENERATIVAS". Esta invenção se refere às piridinas substituídas com arila da fórmula (I) ou um sal farmaceuticamente aceitável, promedicamento ou solvato das mesmas, onde: Ar é selecionado do grupo consistindo em Ar~ 1~, Ar~ 2~, Ar~ 3~, e Ar~ 4~, onde Ar~ 1~ é R~ 1~ selecionado do grupo consistindo em uma alquila opcionalmente substituída, amino, alquiltiol, C(O)R~ 10~, SO~ 2~R~ 10~ e OC(O)NH~ 2~; R~ 2~ é -Y~ m~-(CH~ 2~)~ n~-Z' onde: Y é O, S ou NR~ 11~, onde R~ 11~ é hidrogênio ou alquila, Z é um anel heterocíclico saturado, opcionalmente substituído em um ou mais átomos de carbono, m é 0 ou 1 e n é 0-6; ou um sal farmaceuticamente aceitável, promedicamento ou solvato do mesmo, onde Ar e R~ 1~-R4 são estabelecidos na descrição. A invenção também se refere ao uso dos compostos da fórmula I para o tratamento de dano neuronal seguindo-se a isquemia global e focal, para o tratamento ou prevenção de condições neurodegenerativas, tais como, esclerose amiotrófica lateral (ALS) e para o tratamento, prevenção ou melhora de ambas, dor aguda ou crónica, incluindo neuropatia diabética e agentes antizumbido, como anticonvulsivos, e como depressivos antimaníacos, como anestésicos locais e como antiarrítmicos.
BR0212327-4A 2001-09-07 2002-09-06 Derivados de 2-(d-fenóxi)piridina substituìda heterocìclica e compostos correlatos como bloqueadores de canal de sódio para o tratamento de dano neuronal e condições neurodegenerativas BR0212327A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31745501P 2001-09-07 2001-09-07
PCT/US2002/028299 WO2003022285A1 (en) 2001-09-07 2002-09-06 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions

Publications (1)

Publication Number Publication Date
BR0212327A true BR0212327A (pt) 2004-09-21

Family

ID=23233727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212327-4A BR0212327A (pt) 2001-09-07 2002-09-06 Derivados de 2-(d-fenóxi)piridina substituìda heterocìclica e compostos correlatos como bloqueadores de canal de sódio para o tratamento de dano neuronal e condições neurodegenerativas

Country Status (12)

Country Link
US (1) US6770661B2 (pt)
EP (1) EP1432424A1 (pt)
JP (1) JP2005501916A (pt)
KR (1) KR20040074973A (pt)
AR (1) AR036873A1 (pt)
BR (1) BR0212327A (pt)
CA (1) CA2459531A1 (pt)
HU (1) HUP0500138A3 (pt)
IL (1) IL160714A0 (pt)
MX (1) MXPA04002172A (pt)
RU (1) RU2004110725A (pt)
WO (1) WO2003022285A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538285A (ja) * 2001-07-16 2004-12-24 ユーロ−セルティック エス． ア． アリール置換チアゾリジノンおよびその使用
JP4473583B2 (ja) * 2002-03-13 2010-06-02 ユーロ−セルティーク エス．エイ． アリール置換ピリミジン及びその使用
EP1532119A2 (en) * 2002-07-31 2005-05-25 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
JP4441328B2 (ja) * 2004-05-25 2010-03-31 株式会社ルネサステクノロジ 半導体装置及びその製造方法
BRPI0513717A (pt) 2004-07-23 2008-05-13 Pfizer derivados de piridina
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP4657384B2 (ja) 2007-05-03 2011-03-23 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
CN102223791A (zh) * 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
WO2010044405A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 縮合環誘導体及びその医薬用途
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
CN103153955A (zh) * 2010-09-17 2013-06-12 普渡制药公司 吡啶化合物及其用途
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US9045435B2 (en) 2010-10-05 2015-06-02 Purdue Pharma, L.P. Quinazoline compounds as sodium channel blockers
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
AU2012300567B2 (en) 2011-09-02 2016-03-10 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
WO2013161929A1 (ja) * 2012-04-26 2013-10-31 塩野義製薬株式会社 ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
EP3293184B1 (en) 2013-03-04 2020-12-16 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
CA2939549C (en) 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof
MX2020013099A (es) 2013-06-27 2022-07-26 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
EP3039019B1 (en) 2013-08-26 2020-04-22 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
WO2015094443A1 (en) 2013-12-20 2015-06-25 Purdue Pharma L.P. Pyrimidines and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
CN106103415B (zh) 2013-12-23 2023-02-24 普渡制药公司 吲唑和其用途
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
CN106061944A (zh) 2014-01-24 2016-10-26 普渡制药公司 吡啶类和嘧啶类物质及其用途
CA2939501C (en) 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
MA39956A (fr) 2014-05-06 2015-11-12 Purdue Pharma Lp Analogues du benzomorphane et leur utilisation
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
WO2015192053A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
EP3494105A4 (en) * 2016-05-31 2020-05-13 Human Biomolecular Research Institute COMPOUNDS USED AS SODIUM CHANNEL INHIBITORS

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149109A (en) * 1962-02-20 1964-09-15 Searle & Co Certain 4-trifluoromethyl-2-(oxy/thio) pyrimidines
FR1477021A (fr) 1965-04-21 1967-04-14 Ilford Ltd Matières photographiques
GB1121922A (en) * 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
FR1536093A (fr) 1966-09-10 1968-08-09 Basf Ag Nouvelles amino-4-alcoylmercapto-6-triazines-s
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
US3660414A (en) * 1970-06-01 1972-05-02 Sandoz Ag Certain 5-aryl-2-amino-nicotinonitriles
US3709888A (en) * 1970-06-01 1973-01-09 Sandoz Ag Aryl-substituted-pyrido(2,3-d)pyrimidin-2-ones
US3940404A (en) * 1974-03-06 1976-02-24 The United States Of America As Represented By The Secretary Of The Army 2-Substituted phenyl-6-trifluoromethyl-4-pyridyl-carbinolamines
US3886167A (en) * 1974-03-06 1975-05-27 Us Army 2-Aryl-6-trifluoromethyl-4-pyridylcarbinolamine antimalarials
DE2643753A1 (de) * 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
US4133956A (en) * 1977-07-27 1979-01-09 Eli Lilly And Company Preparation of benzoylureas
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
IL59748A (en) * 1979-04-05 1983-11-30 Lilly Industries Ltd 5-substituted pyranone derivatives,their production and pharmaceutical compositions containing them
JPS56104883A (en) 1980-01-25 1981-08-20 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS56115784A (en) * 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4769462A (en) * 1980-06-02 1988-09-06 American Cyanamid Co. Novel 2-carbamoylnicotinic and 3-quinolinecarboxylic acids and esters
GB2095240A (en) 1981-03-05 1982-09-29 Fujisawa Pharmaceutical Co Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
DE3245950A1 (de) 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
DE3379544D1 (en) * 1982-06-08 1989-05-11 Ciba Geigy Ag 2-phenyl-2-naphthyl and 2-heterocyclic pyrimidines as antidotes for protecting cultured plants before phytotoxic damages caused by herbicides
EP0123700A1 (de) 1983-04-27 1984-11-07 Byk Gulden Lomberg Chemische Fabrik GmbH Substituierte Picolinsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
US4701208A (en) * 1983-08-02 1987-10-20 American Cyanamid Company Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof
DE3685840D1 (de) * 1985-04-30 1992-08-06 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
JPS6320234A (ja) 1986-07-11 1988-01-27 Daihatsu Motor Co Ltd 自動車の２輪・４輪駆動切換装置
PH23565A (en) * 1986-09-05 1989-08-25 Sumitomo Chemical Co Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
GB8627059D0 (en) * 1986-11-12 1986-12-10 Cookson Group Plc Substituted trialine derivatives
ZW21687A1 (en) * 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
US5116989A (en) * 1987-11-06 1992-05-26 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
US5084462A (en) * 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0356672B1 (en) * 1988-07-13 1993-04-07 Canon Kabushiki Kaisha Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
EP0362578A1 (en) 1988-09-14 1990-04-11 E.I. Du Pont De Nemours And Company Treatment of cancer in mammals by concurrent administration of 4-quinoline carboxylic acid derivatives and interleukin-2
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
GB8906470D0 (en) 1989-03-21 1989-05-04 Cookson Group Plc Photopolymerisable composition
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
US5403934A (en) * 1990-03-12 1995-04-04 Burroughs Wellcome Co. Heterocyclic compounds
EP0446604A3 (en) 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
NZ239946A (en) 1990-09-28 1994-09-27 Smith Kline French Lab 3-(tetrazol-5-yl)-6-(substituted phenyl)pyridine derivatives and medicaments
US5187481A (en) 1990-10-05 1993-02-16 Hewlett-Packard Company Combined and simplified multiplexing and dithered analog to digital converter
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0507962B1 (en) 1990-10-25 2001-06-13 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative, production thereof, and herbicide
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
GB9124578D0 (en) 1991-11-20 1992-01-08 Smithkline Beecham Plc Chemical compounds
US5389632A (en) * 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
TW237456B (pt) * 1992-04-09 1995-01-01 Ciba Geigy
JPH0776542A (ja) 1993-09-06 1995-03-20 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5744492A (en) * 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6057346A (en) * 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
EP0854721B1 (en) * 1995-08-02 2001-10-24 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
AU738197C (en) 1997-04-22 2002-05-16 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
PL344861A1 (en) 1997-12-12 2001-11-19 Abbott Lab Trazinic angiogenesis inhibitiors
JP4321737B2 (ja) * 1997-12-17 2009-08-26 塩野義製薬株式会社 新規ピリジン化合物
KR20010032643A (ko) 1997-12-19 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 아닐리드 유도체, 그의 제조 및 용도
US6562817B1 (en) 1998-01-28 2003-05-13 Shionogi & Co., Ltd. Tricyclic compound
CA2352612A1 (en) 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
EP1140901A2 (en) 1998-12-24 2001-10-10 Aventis Pharmaceuticals Products Inc. Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
DE20080291U1 (de) * 1999-03-26 2002-06-27 Euro-Celtique S.A., Luxemburg/Luxembourg Aryl-substituierte Pyrazole, Imidazole, Oxazola, Thiazole und Pyrrole
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
KR20020080378A (ko) * 2000-01-20 2002-10-23 에자이 가부시키가이샤 신규 피페리딘 화합물 및 그의 의약
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1292577B1 (en) * 2000-03-24 2012-10-24 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
JP2003529589A (ja) * 2000-03-31 2003-10-07 ユーロ−セルティック エス． ア． アミノピリジンならびにこれらの鎮痙薬およびナトリウムチャンネル遮断薬としての使用
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体

Also Published As

Publication number Publication date
AR036873A1 (es) 2004-10-13
RU2004110725A (ru) 2005-10-10
MXPA04002172A (es) 2004-07-23
HUP0500138A3 (en) 2005-07-28
CA2459531A1 (en) 2003-03-20
WO2003022285A1 (en) 2003-03-20
HUP0500138A2 (hu) 2005-05-30
US20030073724A1 (en) 2003-04-17
JP2005501916A (ja) 2005-01-20
IL160714A0 (en) 2004-08-31
KR20040074973A (ko) 2004-08-26
US6770661B2 (en) 2004-08-03
EP1432424A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
BR0212327A (pt) Derivados de 2-(d-fenóxi)piridina substituìda heterocìclica e compostos correlatos como bloqueadores de canal de sódio para o tratamento de dano neuronal e condições neurodegenerativas
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BR0212338A (pt) Piridino-carboxamidas aril-substituìdas e seu emprego como bloqueadores de canais de sódio
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
PT1178045E (pt) Derivados de azaindole-etilamina como agentes de ligacao de receptores de acetilcolina nicotinicos
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
NO20023218L (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
PT1161428E (pt) Compostos de pirimidina
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
BRPI0509824A (pt) compostos heterocìclicos [3.2.0] e métodos de uso dos mesmos
EA200100376A1 (ru) Арилсульфонанилидмочевины
DE69519469D1 (de) Chinazolin-derivate
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0412502A (pt) derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
BR0009278A (pt) 1-arenossulfonil-2-aril-pirrolidina e derivados depiperidina
NO20023977L (no) 8,8A-dihydro-indeno(1,2-D)tiazolderivater med en sulfonamid- eller sulfonsubstituent i 2-posisjonen, deres fremstilling oganvendelse
DK0992509T3 (da) Nye makrolid-derivater
DK1847534T3 (da) Thiadiazolin-derivater til behandling af kræft
DK1340757T3 (da) 1-methylcarbapenemderivater
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
PT1209166E (pt) Novos derivados de a-500359
DE60135016D1 (de) Indolderivate und deren verwendung in medikamenten
DK0922054T3 (da) Antikoagulerende peptidylargininaldehydderivater

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]